Compare Natera Inc. Common Stock (NTRA) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Virgin Galactic Holdings, Inc. — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Virgin Galactic Holdings, Inc. trades at $2.54 (market cap $398.70M). The key difference: Natera Inc. Common Stock is far larger — about 143× Virgin Galactic Holdings, Inc.'s market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Virgin Galactic Holdings, Inc. for 70 Days on average.
| NTRA | SPCE | |
|---|---|---|
Market Cap | $57.03B | $398.70M |
Volume | 1,131,157 | 5,790,856 |
Sector | Health | Industrials |
52-Week High | $425.64 | $7.52 |
52-Week Low | $179.42 | $2.17 |
Typical Hold Time | 0 Days | 70 Days |
Enterprise Value | $56.18B | $362.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Virgin Galactic (SPCE) trades at $2.55, down 4.49% on the day, reflecting ongoing investor concerns about delayed commercial operations. The company continues to report significant losses with negative profit margins exceeding 23,800% and negative cash flow, though recent earnings have beaten expectations. Technical indicators show a bearish trend with oversold conditions, while management maintains guidance for positive cash flow by 2027.
The outlook remains highly speculative with substantial execution risk. While space tourism represents a long-term growth opportunity, SPCE faces persistent financial challenges including cash burn, stock dilution, and competitive pressures. Analyst sentiment is divided with no clear consensus, making this suitable only for risk-tolerant investors betting on successful commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
